The effect of a human plasma thymic factor on human peripheral blood mononuclear cell subpopulations.

Levai JS, Utermohlen V

Clinical immunology and immunopathology1 Jun 1983Cited by 4 (Europe PMC)

PMID6409484DOI10.1016/0090-1229(83)90095-8PepBankPUB-06409484

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS significantly increased avid E-rosette formation.
In plain wordsIn lab tests, FTS increased avid E-rosette formation in human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseAvid E-rosette formation
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948401
02LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS increased the percentage of OKT8-positive cells.
In plain wordsIn lab tests, FTS increased the percentage of OKT8-positive human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseOKT8-positive cell percentage
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
It also increased the percentage of OKT8+ cells but did not affect the percentages of OKT3+, OKT4+, OKT11+, OKIa1+, or OKM+ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948402
03LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS did not affect the percentage of OKT3-positive cells.
In plain wordsIn lab tests, FTS did not change the percentage of OKT3-positive human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeOKT3-positive cell percentage
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
It also increased the percentage of OKT8+ cells but did not affect the percentages of OKT3+, OKT4+, OKT11+, OKIa1+, or OKM+ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948403
04LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS did not affect the percentage of OKT4-positive cells.
In plain wordsIn lab tests, FTS did not change the percentage of OKT4-positive human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeOKT4-positive cell percentage
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
It also increased the percentage of OKT8+ cells but did not affect the percentages of OKT3+, OKT4+, OKT11+, OKIa1+, or OKM+ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948404
05LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS did not affect the percentage of OKT11-positive cells.
In plain wordsIn lab tests, FTS did not change the percentage of OKT11-positive human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeOKT11-positive cell percentage
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
It also increased the percentage of OKT8+ cells but did not affect the percentages of OKT3+, OKT4+, OKT11+, OKIa1+, or OKM+ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948405
06LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS did not affect the percentage of OKIa1-positive cells.
In plain wordsIn lab tests, FTS did not change the percentage of OKIa1-positive human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeOKIa1-positive cell percentage
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
It also increased the percentage of OKT8+ cells but did not affect the percentages of OKT3+, OKT4+, OKT11+, OKIa1+, or OKM+ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948406
07LabIn vitro (cells)Activity measurement
In human peripheral blood mononuclear cells, FTS did not affect the percentage of OKM-positive cells.
In plain wordsIn lab tests, FTS did not change the percentage of OKM-positive human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeOKM-positive cell percentage
Study
humann: not reported in source
peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
It also increased the percentage of OKT8+ cells but did not affect the percentages of OKT3+, OKT4+, OKT11+, OKIa1+, or OKM+ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Human plasma thymic factor in vitro (human "facteur thymique sérique," or FTS) (at concentrations between 0.25 and 0.25 X 10(5) pg/ml) significantly increased "avid" E-rosette formation by human peripheral blood mononuclear cells (PBMC).
Report a problemFND-0640948407
08LabIn vitro (cells)Activity measurement
In low-density immature human blood mononuclear cells, FTS increased total E-rosette formation.
In plain wordsIn lab tests, FTS increased total E-rosette formation in immature human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseTotal E-rosette formation
Study
humann: not reported in source
low-density immature peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
In the low-density immature PBMC, FTS increased both total and avid E-rosette formation, while increasing the percentages of OKT3+ and OKT8+ cells and decreasing the percentage of OKT4+ cells.
Report a problemFND-0640948408
09LabIn vitro (cells)Activity measurement
In low-density immature human blood mononuclear cells, FTS increased avid E-rosette formation.
In plain wordsIn lab tests, FTS increased avid E-rosette formation in immature human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseAvid E-rosette formation
Study
humann: not reported in source
low-density immature peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
In the low-density immature PBMC, FTS increased both total and avid E-rosette formation, while increasing the percentages of OKT3+ and OKT8+ cells and decreasing the percentage of OKT4+ cells.
Report a problemFND-0640948409
10LabIn vitro (cells)Activity measurement
In low-density immature human blood mononuclear cells, FTS increased the percentage of OKT3-positive cells.
In plain wordsIn lab tests, FTS increased the percentage of OKT3-positive immature human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseOKT3-positive cell percentage
Study
humann: not reported in source
low-density immature peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
In the low-density immature PBMC, FTS increased both total and avid E-rosette formation, while increasing the percentages of OKT3+ and OKT8+ cells and decreasing the percentage of OKT4+ cells.
Report a problemFND-0640948410
11LabIn vitro (cells)Activity measurement
In low-density immature human blood mononuclear cells, FTS increased the percentage of OKT8-positive cells.
In plain wordsIn lab tests, FTS increased the percentage of OKT8-positive immature human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseOKT8-positive cell percentage
Study
humann: not reported in source
low-density immature peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
In the low-density immature PBMC, FTS increased both total and avid E-rosette formation, while increasing the percentages of OKT3+ and OKT8+ cells and decreasing the percentage of OKT4+ cells.
Report a problemFND-0640948411
12LabIn vitro (cells)Activity measurement
In low-density immature human blood mononuclear cells, FTS decreased the percentage of OKT4-positive cells.
In plain wordsIn lab tests, FTS decreased the percentage of OKT4-positive immature human blood mononuclear cells.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseOKT4-positive cell percentage
Study
humann: not reported in source
low-density immature peripheral blood mononuclear cells
Outcome group
Immune response · Immune and inflammation
Studied dose
0.25 to 0.25 X 10(5) pg/mlAs given in this study (human).
Source sentences
Summary
In the low-density immature PBMC, FTS increased both total and avid E-rosette formation, while increasing the percentages of OKT3+ and OKT8+ cells and decreasing the percentage of OKT4+ cells.
Report a problemFND-0640948412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.